Akèy › Kansè (tout kalite) › Utah › Salt Lake City
Etid klinik pou Kansè (tout kalite) nan Salt Lake City, UT
27 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Salt Lake City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Intermountain - Primary Children's Hospital ( Site 4014), Salt Lake City
SAFE.AI: Developing and Testing an AI-based Hybrid Chatbot for Financial Empowerment in Rural Cancer Care
Ap rekrite
- Huntsman Cancer Institute/ University of Utah, Salt Lake City
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Ap rekriteFaz 3
- Utah Cancer Specialists Cancer Center - Medical Oncology, Salt Lake City
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
Ap rekriteFaz 2
- Intermountain Healthcare, Salt Lake City
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- University of Utah - Huntsman Cancer Institute, Salt Lake City
- Intermountain Healthcare - LDS Hospital, Salt Lake City
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
Ap rekriteFaz 1/2
- Intermountain - Primary Children's Hospital ( Site 3014), Salt Lake City
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- Huntsman Cancer Institute - University of Utah Health, Salt Lake City
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1/2
- Huntsman Cancer Institute /ID# 271618, Salt Lake City
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, Salt Lake City
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Primary Children's Hospital, Salt Lake City
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Ap rekriteFaz 3
- University of Utah, Salt Lake City
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Ap rekriteFaz 3
- University of Utah Sugarhouse Health Center, Salt Lake City
- Huntsman Cancer Institute/University of Utah, Salt Lake City
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Ap rekriteFaz 1/2
- Huntsman Cancer Institute /ID# 272575, Salt Lake City
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
Ap rekrite
- Huntsman Cancer Institute at The University of Utah, Salt Lake City
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Ap rekrite
- VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City
Heuristic Tool To Improve Symptom Self-Management in Adolescents and Young Adults With Cancer
Ap rekrite
- University of Utah Huntsman Cancer Institute (HCI), Salt Lake City
- University of Utah Primary Children's Hospital, Salt Lake City
Galleri® in the Medicare Population.
Ap rekriteVolontè an sante akeyi
- HCA Healthcare St. Marks, Salt Lake City
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Ap rekrite
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
Improving Health Insurance Literacy Among Young Adult Cancer Survivors
Ap rekrite
- University of Utah, Salt Lake City
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Huntsman Cancer Institute, University of Utah, Salt Lake City
Enhancing Motivation to Quit Smoking Via Self-Help Intervention Targeted to Cancer Type
Ap rekrite
- Huntsman Cancer Institute, Salt Lake City
Childhood Cancer Predisposition Study (CCPS)
Ap rekriteEtid obsèvasyon
- Primary Children's Hospital, Salt Lake City
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Salt Lake City
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
Ap rekriteEtid obsèvasyon
- Utah Cancer Specialists, Salt Lake City
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Ap rekrite
- Huntsman Cancer Institute (The University of Utah), Salt Lake City
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY109 etid
- Boston, MA85 etid
- Los Angeles, CA74 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Washington, DC58 etid
- Durham, NC58 etid
- Chicago, IL51 etid
- Atlanta, GA49 etid
- Seattle, WA49 etid
- Arlington, VA48 etid
Lòt etid nan Salt Lake City
- Kansè Poumon ki pa ti selil31 etid
- Kansè nan tete27 etid
- Kansè kolorektal22 etid
- Kansè poumon21 etid
- Melanom21 etid
- Myelom Miltip21 etid
- Kansè Metastatik20 etid
- Kansè ovè19 etid
- Obèsite18 etid
- Leksemi mieloïd egi17 etid
- Ensifizyans kadyak17 etid
- Kansè pwostat15 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.